Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

Gynecologic Oncology

Volumn 130, Issue 2, 2013, Pages 269-274

  Tinker, A V ^a   Ellard, S ^a   Welch, S ^b   Moens, F ^c   Allo, G ^d   Tsao, M S ^d   Squire, J ^e   Tu, D ^e   Eisenhauer, E A ^e   MacKay, H ^d  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

Cervical cancer systemic therapy Temsirolimus Phase II trial mTOR pathway

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; TEMSIROLIMUS;

ABDOMINAL PAIN; ACNEIFORM RASH; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; EDEMA; FATIGUE; FEMALE; FEMALE GENITAL TRACT FISTULA; FISTULA; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; METASTASIS; METHYLATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA; VOMITING;

CERVICAL CANCER SYSTEMIC THERAPY; MTOR PATHWAY; PHASE II TRIAL; TEMSIROLIMUS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; SIROLIMUS; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84880289115     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.008     Document Type: Article

References (28)

1. L.A.G. Ries, M.P. Eisner, C.L. Kosary, B.F. Hankey, B.A. Miller, and L. Clegg SEER cancer statistics review 1975-2000 2003 National Cancer Institute Bethesda
2. A.W. Fyles, M. Pintilie, P. Kirkbride, W. Levin, L.A. Manchul, and G.A. Rawlings Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis Radiother Oncol 35 2 May 1995 107 117
3. H.J. Long 3rd, B.N. Bundy, E.C. Grendys Jr., J.A. Benda, D.S. McMeekin, and J. Sorosky Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study J Clin Oncol 23 21 Jul 20 2005 4626 4633
4. D.H. Moore, J.A. Blessing, R.P. McQuellon, H.T. Thaler, D. Cella, and J. Benda Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 22 15 Aug 1 2004 3113 3119
5. B.J. Monk, M.W. Sill, D.S. McMeekin, D.E. Cohn, L.M. Ramondetta, and C.H. Boardman Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study J Clin Oncol 27 28 Oct 1 2009 4649 4655
6. X.Y. Zhang, H.Y. Zhang, P.N. Zhang, X. Lu, and H. Sun Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer Eur J Obstet Gynecol Reprod Biol 139 2 Aug 2008 237 244
7. W. Feng, X. Duan, J. Liu, J. Xiao, and R.E. Brown Morphoproteomic evidence of constitutively activated and overexpressed mTOR pathway in cervical squamous carcinoma and high grade squamous intraepithelial lesions Int J Clin Exp Pathol 2 3 2009 249 260
8. N. Hay, and N. Sonenberg Upstream and downstream of mTOR Genes Dev 18 16 Aug 15 2004 1926 1945
9. Z. Lu, X. Hu, Y. Li, L. Zheng, Y. Zhou, and H. Jiang Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin J Biol Chem 279 34 Aug 20 2004 35664 35670
10. A.C. Gingras, B. Raught, and N. Sonenberg Regulation of translation initiation by FRAP/mTOR Genes Dev 15 7 Apr 1 2001 807 826
11. A.A. Molinolo, C. Marsh, M. El Dinali, N. Gangane, K. Jennison, and S. Hewitt mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas Clin Cancer Res 18 9 May 1 2012 2558 2568
12. G. Hudes, M. Carducci, P. Tomczak, J. Dutcher, R. Figlin, and A. Kapoor Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 22 May 31 2007 2271 2281
13. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, and S. Bracarda Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 9637 Aug 9 2008 449 456
14. G. Hess, R. Herbrecht, J. Romaguera, G. Verhoef, M. Crump, and C. Gisselbrecht Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 23 Aug 10 2009 3822 3829
15. J.C. Yao, M.H. Shah, T. Ito, C.L. Bohas, E.M. Wolin, and E. Van Cutsem Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 6 Feb 10 2011 514 523
16. E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, and R. Ford New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2 Jan 2009 228 247
17. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin Trials 10 1 Mar 1989 1 10
18. M. Yoshimoto, J. Bayani, P.A. Nuin, N.S. Silva, S. Cavalheiro, and J.N. Stavale Metaphase and array comparative genomic hybridization: unique copy number changes and gene amplification of medulloblastomas in South America Cancer Genet Cytogenet 170 1 Oct 1 2006 40 47
19. I. Akagi, M. Miyashita, H. Makino, T. Nomura, N. Hagiwara, and K. Takahashi Overexpression of PIK3CA is associated with lymph node metastasis in esophageal squamous cell carcinoma Int J Oncol 34 3 Mar 2009 767 775
20. M. Yoshimoto, I.W. Cunha, R.A. Coudry, F.P. Fonseca, C.H. Torres, and F.A. Soares FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome Br J Cancer 97 5 Sep 3 2007 678 685
21. B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 27 7 Mar 1 2009 1069 1074
22. I. Diaz-Padilla, I. Duran, B.A. Clarke, and A.M. Oza Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer Cancer Treat Rev 38 6 Oct 2012 767 775
23. B.J. Monk, L. Mas Lopez, J.J. Zarba, A. Oaknin, C. Tarpin, and W. Termrungruanglert Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 22 Aug 1 2010 3562 3569
24. K.K. Ward, N.R. Shah, C.C. Saenz, M.T. McHale, E.A. Alvarez, and S.C. Plaxe Changing demographics of cervical cancer in the United States (1973-2008) Gynecol Oncol 126 3 Sep 2012 330 333
25. L.T. Gien, M.C. Beauchemin, and G. Thomas Adenocarcinoma: a unique cervical cancer Gynecol Oncol 116 1 Jan 2010 140 146
26. M. Gerlinger, A.J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, and E. Gronroos Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 10 Mar 8 2012 883 892
27. J.N. McAlpine, A. Bashashati, G. Ha, J. Rosner, J. Ding, and K. Shumansky Intratumoral heterogeneity in high-grade serous cancers: defining evolution of the somatic mutational landscape across spatially and temporally selected samples IGCS 2012:Plenary Session 2012
28. S.P. Shah, R.D. Morin, J. Khattra, L. Prentice, T. Pugh, and A. Burleigh Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution Nature 461 7265 Oct 8 2009 809 813